Head-to-head · WeighScore
Gimme Care vs Mint Med
The verdict
Gimme Care takes it — 84.6/100 to 78.7/100.
Gimme Care grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mid-value both-molecule pricing ($130/$163), verified, and nationwide.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Gimme Care | Mint Med |
|---|---|---|
| WeighScore | 84.6/100 | 78.7/100 |
| Grade | B | C+ |
| Scorecard rank | #17 | #42 |
| Semaglutide | $130/mo | $117/mo |
| Tirzepatide | $163/mo | $159/mo |
| Coverage | All 50 states | 36 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #17 · B
Strengths
- $130 sema / $163 tirz
- All 50 states, LegitScript-verified
- Both molecules
Where it loses points
- Not the cheapest tier
- Injection-only
- Monitoring detail limited
Graded #42 · C+
FDAWarning letter issued to Glow Medispa, LLC dba Mint Med in June 2026. See the FDA warning-letter database.
Strengths
- $117 sema / $159 tirz
- LegitScript-verified
- Both molecules
Where it loses points
- Only 36 states
- Injection-only
- Monitoring detail sparse
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 509 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.